Arcreal Plans U.S. Entry with $5.4M in New Funding

The South Korean AI healthcare company has raised $5.4 million to advance its AI technology and support expansion of its arcscan intraoral scanner into U.S. and European markets.

Arcreal, a South Korean AI healthcare company, has raised $5.4 million (8 billion KRW) in Pre-Series A funding to support further development of its intraoral scanner and AI models, and to prepare for expansion into the U.S. market. The company plans to establish a U.S. subsidiary in 2026. Its scanner, arcscan, has received FDA clearance.

Funding and Expansion Plans

The round included investments from DSC Investment, SDB Investment, Schmidt, and Soo Investment Capital. With this latest funding, Arcreal’s total capital raised now stands at $9.6 million (14.1 billion KRW). The funding will be used to advance the company’s AI models and accelerate global commercialization of arcscan. The product has also received CE MDR approval in Europe.

Intraoral Scanner Development

The arcscan intraoral scanner has been developed entirely in-house, including the hardware, software, AI models, and platforms. According to the company, arcscan offers performance comparable to premium products from major global brands while maintaining a proprietary design intended to reduce costs.

Leadership and Technical Oversight

CEO Seunghyun Jeon and CTO Kyungguk Kim lead the company’s technology strategy. Jinwoo Shin, Chair Professor at KAIST AI Graduate School, oversees AI research.

Shin said, “Arcreal has established a foundation to directly secure the most precise 3D oral data globally. Based on this, we are accelerating the completion of a 3D vision foundation model specialized in oral structures that understands complex anatomical information such as teeth, gums, and occlusion. Once the model is complete, the dental field will expand beyond automation to personalized patient treatment and predictive medicine, and Arcreal will lead that transformation.”

Investor Perspective

Junghoon Kim, executive director at SDB Investment, said, “We have highly valued the Arcreal team’s technology and execution capabilities since the seed stage. The continued participation of existing investors clearly demonstrates that trust. Arcreal is a team that will lead innovation in the global market, starting with intraoral scanners, the first gateway to digital dentistry.”